vonaprument
vonaprument: developed by 1 company · 1 clinical trial tracked.
vonaprument evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could vonaprument → ANNX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Annexon, Inc. (ANNX) | Phase 3 |
Clinical Trials (1)
A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 (Vonaprument) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy
Primary endpoint: Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits
Frequently asked questions
Who is developing vonaprument?
vonaprument is being developed by Annexon, Inc..
How many clinical trials involve vonaprument?
BioSniper tracks 1 clinical trial involving vonaprument.